Shots:
- Brazil’s ANVISA has approved marketing authorization for Formycon’s Ranivisio (ranibizumab), a biosimilar to Lucentis; launch is anticipated in Q4’25
- Formycon & Biomm have partnered to commercialize Ranivisio in Latin America, with approvals already granted in Peru, El Salvador, Honduras, and the Dominican Republic. Additional launches across Central and South America are planned through early 2027
- Ranivisio (FYB201), developed by Bioeq AG, a joint venture of Formycon & Polpharma Biologics, treats conditions like wet AMD and other retinopathies. It is available in 21 countries across Europe, North America, and the MENA region
Ref: Formycon | Image: Formycon | Press Release
Related News:- Formycon Reports the MHRA’s Approval of FYB203 (Biosimilar, Eylea) as Ahzantive
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
